• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Liquidia Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    6/18/25 4:30:39 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LQDA alert in real time by email
    false 0001819576 0001819576 2025-06-16 2025-06-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 16, 2025

     

    LIQUIDIA CORPORATION
    (Exact name of registrant as specified in its charter)
         
    Delaware 001-39724 85-1710962
    (State or other jurisdiction
    of incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)

     

    419 Davis Drive, Suite 100, Morrisville, North Carolina 27560
    (Address of principal executive offices) (Zip Code)

     

    Registrant’s telephone number, including area code: (919) 328-4400 

    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common stock LQDA The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 1.01 Entry Into a Material Definitive Agreement.

     

    On June 16, 2025, Liquidia Technologies, Inc., a Delaware corporation (the “Tenant”) and a wholly owned subsidiary of Liquidia Corporation, a Delaware corporation (the “Company”), entered into an Indenture of Lease (the “Lease”), dated as of June 16, 2025, with King Combs LLC, a Delaware limited liability company (the “Landlord”). The Lease is for the Company’s new manufacturing facility, which is approximately 70,131 rentable square feet (the “Premises”) at Pathway Triangle Building 1, 1000 Science Drive, Morrisville, North Carolina, 27560 (the “Building”).

     

    The Lease provides for a term commencing upon June 16, 2025 and expiring on November 1, 2036. Under the terms of the Lease, the Tenant has the option to extend the Lease two times, each for a period of five additional years, by providing written notice to the Landlord not more than 18 months nor less than 12 months prior to the then-current expiration date. In addition, during the term of the Lease, the Lease also provides the Tenant with a one-time “right of first offer” with respect to any space contiguous to the Premises in the Building, when such space becomes available for lease, subject to any terms provided by the Landlord in connection with the offer to lease such space.

     

    Beginning on May 1, 2026 (the “Term Commencement Date”), the Company’s monthly base rent under the Lease will be $260,069.13 for the first 12-month term, which will increase by 3.0% per each subsequent 12-month term; provided, that base rent will be abated during the first six months after the Term Commencement Date. The Tenant will also be responsible for paying operating expenses from and after the Term Commencement Date.

     

    The Lease contains customary representations, warranties, and covenants.

     

    The foregoing description of the Lease is not complete and is qualified in its entirety by reference to the complete terms and conditions of the Lease. A copy of the Lease will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the period ending June 30, 2025.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit
    No.
      Exhibit
    104   Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    June 18, 2025 Liquidia Corporation
       
      By: /s/ Michael Kaseta
        Name: Michael Kaseta
        Title: Chief Financial Officer and Chief Operating Officer

     

     

     

    Get the next $LQDA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LQDA

    DatePrice TargetRatingAnalyst
    5/19/2025$13.00Perform → Underperform
    Oppenheimer
    12/20/2024$20.00Overweight
    Wells Fargo
    10/16/2024Sector Outperform
    Scotiabank
    8/19/2024Outperform → Strong Buy
    Raymond James
    8/16/2024$27.00Outperform
    Raymond James
    6/25/2024Perform
    Oppenheimer
    1/5/2024$18.00 → $28.00Buy
    Needham
    9/19/2022$3.00Underperform
    Wedbush
    More analyst ratings

    $LQDA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD

      YUTREPIA now available to be prescribed to patients via specialty pharmaciesFDA approved YUTREPIA on May 23, 2025Court denies United Therapeutics' request for preliminary injunction and a temporary restraining order, clearing the path for full commercial launch MORRISVILLE, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that Liquidia is scheduled to make its first commercial shipment of YUTREPIA™ (treprostinil) inhalation powder, marking the first time YUTREPIA will be available to be prescribed to patients at specialty pharmacies. This m

      6/2/25 6:30:00 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference

      MORRISVILLE, N.C., May 28, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today that the company's Chief Executive Officer Dr. Roger Jeffs, Chief Financial Officer and Chief Operating Officer Michael Kaseta, and Chief Business Officer Jason Adair will be providing an update on the company's business during a fireside chat at the 2025 Jefferies Global Healthcare Conference on Wednesday June 4, 2025, beginning at 11:05 a.m. ET, in New York City.Access to a webcast will be available to investors and other interested parties by accessing Liquidia's website at https://liquidia.com/investors/events-and-presentations. An archived, recorded version of the presentation will b

      5/28/25 8:00:00 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • U.S. FDA Approves Liquidia's YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

      FDA's approval of YUTREPIA paves the way for prescribers to add a new treatment option for patients with PAH and PH-ILDYUTREPIA is designed to enhance deep-lung delivery with an easy-to-use device requiring low inspiratory effortDemonstrated tolerability and titratability in the pivotal INSPIRE studyLiquidia will host a webcast Tuesday, May 27, 2025 at 8:30 a.m. ET to provide an update on commercial launch preparations MORRISVILLE, N.C., May 23, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that the U.S. Food and Drug Administration (FDA) has appro

      5/23/25 2:28:40 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LQDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Liquidia Technologies downgraded by Oppenheimer with a new price target

      Oppenheimer downgraded Liquidia Technologies from Perform to Underperform and set a new price target of $13.00

      5/19/25 8:49:50 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Liquidia Technologies with a new price target

      Wells Fargo initiated coverage of Liquidia Technologies with a rating of Overweight and set a new price target of $20.00

      12/20/24 7:42:58 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Liquidia Technologies

      Scotiabank initiated coverage of Liquidia Technologies with a rating of Sector Outperform

      10/16/24 8:39:33 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care